Viatris, Inc. VTRS

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it was named to Forbes' World's Best Employers list for the sixth consecutive year. The ranking is presented by Forbes and Statista, the world-leading statistics portal and industry ranking provider, and is based on independent employee feedback collected globally, highlighting employee trust, workplace experience and organizational culture at Viatris.

Investing.com -- Viatris filed a lawsuit against Novo Nordisk in Delaware federal court, requesting a determination that its planned generic version of Wegovy would not violate the Danish company's patent rights.

Viatris has comfortably outperformed the broader S&P 500 over the past year, with analysts maintaining a fairly bullish outlook on the stock.

Viatris Inc. (NASDAQ:VTRS) announced on September 16 that Japan’s Ministry of Health, Labour and Welfare approved WAKIX, or pitolisant, for narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome in patients receiving treatment for airway obstruction. The narcolepsy approval covers types 1 and 2, with and without cataplexy, or sudden muscle weakness. The […]

A new US law that could slap tariffs of up to 100% on imports from big buyers of Russian energy, including India, suddenly puts long trusted trade routes in question and opens the door for alternative suppliers. That shift creates a potential opening for US-focused stocks exposed to this news, and investors who ignore it risk missing a meaningful realignment in global sourcing. This article examines the law’s potential ripple effects and highlights 3 stocks from the screener that could be...

Gilead Sciences (NASDAQ:GILD) has expanded six existing royalty-free voluntary licensing agreements to include an investigational once-yearly formulation of lenacapavir for HIV prevention, the company announced. The expanded agreements cover 120 countries with high HIV incidence, primarily low- and lower-middle-income nations.

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that Japan's Ministry of Health, Labour and Welfare has granted approval for WAKIX® (pitolisant) for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS) in patients receiving treatment for airway obstruction, and approval for narcolepsy (type 1 and 2 – with and without cataplexy). WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan fo

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 30% gain over the past six months, beating the S&P 500 by 16.7 percentage points.

The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Why recent generic drug earnings matter for Viatris stock Recent earnings across the generic drug industry highlighted steady demand alongside pricing and supply challenges, putting fresh attention on how Viatris (VTRS) is using new launches, product mix, and cost discipline to support its business. At a share price of US$16.34, Viatris has seen some short term pressure, with the 1 day share price return declining 3.26% and the 1 month share price return down 8.31%. However, the year to date...

Cavendish has reiterated its buy rating on Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF) following the pharmaceutical company's agreement to take full commercial control of its main United States (US) product from Viatris. The broker kept its target price at 23 pence, implying potential...

Forget the humanoid robots for a minute; the most potent catalyst for the stock may already be hitting the streets, and it's growing exponentially.

Management put a stunning new number on its full-year earnings, and the market is buying the story. But the real question is whether this is a new era of growth or customers pulling forward tomorrow's demand into today.